证券代码：301080 证券简称：百普赛斯 公告编号：2025-070 为进一步推动国际化战略落地，加强海外业务布局，拓宽海内外并购和融资 渠道，提高公司国际知名度，提高公司整体竞争力，根据公司总体发展战略及运 营需要，公司拟在境外发行股份（H 股）并在香港联合交易所有限公司（以下简 称"香港联交所"）上市（以下简称"本次 H 股发行上市"）。公司董事会同 意授权公司管理层启动本次 H 股发行上市的相关前期筹备工作。 截至目前，本次 H 股发行上市的相关细节尚未确定。根据《深圳证券交易 所创业板股票上市规则》《境内企业境外发行证券和上市管理试行办法》等法律、 法规和规范性文件的要求，待确定具体方案后，本次 H 股发行上市尚需提交公 司董事会和股东会审议，并需取得中国证券监督管理委员会和香港联交所等相关 政府机构、监管机构备案、批准或核准。本次 H 股发行上市能否通过审议、备 案和审核批准程序并最终实施具有不确定性。 公司将依据相关法律、法规、规范性文件的规定，根据本次 H 股发行上市 申请的后续进展情况及时履行信息披露义务。公司指定信息披露媒体为《中国证 券报》《上海证券报》《证券时报》及巨潮资讯网（www. ...

北京百普赛斯生物科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第四次临时股东会 证券代码：301080 证券简称：百普赛斯 公告编号：2025-072 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交 易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— 创业板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及 《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 13 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间 为 2025 年 11 月 13 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易 所互联网投票系统投票的具体时间为 2025 年 11 月 13 日 9:15 至 15:00 的任意 时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登 ...

北京百普赛斯生物科技股份有限公司（以下简称"公司"）第二届董事会第二 十二次会议于 2025 年 10 月 28 日上午 8:30 在北京市北京经济技术开发区宏达北 路 8 号公司会议室以通讯表决和现场表决的方式召开。本次会议通知及会议资料 于 2025 年 10 月 23 日以专人送达、传真、电子邮件的方式发出。会议应出席董 事 7 人，实际出席董事 7 人：参与现场会议的董事 1 人；参与通讯会议的董事 6 人，分别为苗景赟先生、屈文婷女士、李杨女士、许娟红女士、刘峰先生、张勇 先生。会议由董事长陈宜顶先生主持，公司高级管理人员列席会议。会议的召集、 召开符合法律、法规、规则和《公司章程》规定。 证券代码：301080 证券简称：百普赛斯 公告编号：2025-066 北京百普赛斯生物科技股份有限公司 第二届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 参会的董事一致同意通过如下决议： （一）审议通过《关于公司<2025 年第三季度报告>的议案》 经审核，董事会认为公司《2025 ...

公司于 2023 年 7 月 17 日召开第一届董事会第二十五次会议审议通过了《关 于回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购 公司部分已发行的人民币普通股股份，用于员工持股计划或股权激励（以下简称 "第一期回购"）。本次用于回购股份的资金总额不低于人民币 1,500 万元且不超 过人民币 3,000 万元（均包含本数）。 证券代码：301080 证券简称：百普赛斯 公告编号：2025-068 北京百普赛斯生物科技股份有限公司 关于变更部分回购股份用途并注销的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 北京百普赛斯生物科技股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第二届董事会第二十二次会议，审议通过了《关于变更部分回购股份用途 并注销的议案》，根据《深圳证券交易所上市公司自律监管指引第 9 号——回购 股份》（以下简称《自律监管指引》）的规定以及公司《关于回购公司股份的回 购报告书》（公告编号：2023-033），公司拟将回购专用证券账户中第一期回购 的部分股份用途由"用于员工持股计划或股权激 ...

Core Viewpoint - The company, Baipusais (301080.SZ), announced plans to initiate the process for issuing H-shares and listing on the Hong Kong Stock Exchange, aiming to enhance its international strategy and expand its overseas business presence [1] Group 1 - The meeting to review the proposal is scheduled for October 28, 2025 [1] - The initiative is intended to broaden financing channels and improve international visibility and overall competitiveness [1] - Details regarding the proposal are not yet finalized and will require approval from the company's board, shareholders, and relevant government and regulatory bodies [1]

Core Insights - The company reported third-quarter revenue of 226 million, representing a year-over-year increase of 37.50% [1] - Net profit for the third quarter was 48.62 million, showing a year-over-year growth of 81.46% [1] - For the first three quarters, total revenue reached 613 million, reflecting a year-over-year increase of 32.26% [1] - Net profit for the first three quarters amounted to 132 million, with a year-over-year growth of 58.61% [1]

Core Viewpoint - The company plans to change the purpose of the remaining 57,803 shares from the first phase of the buyback from "for employee stock ownership plan or equity incentives" to "for cancellation and corresponding reduction of registered capital" [1] Group 1 - The company will also proceed with the cancellation of 612,700 shares from the second phase of the buyback [1] - A total of 670,500 shares will be canceled as part of the first and second phase buyback plans [1] - Following the cancellations, the company's total share capital will decrease from 168 million shares to 167 million shares [1]

北京百普赛斯生物科技股份有限公司 2025 年第三季度报告 证券代码：301080 证券简称：百普赛斯 公告编号：2025-067 北京百普赛斯生物科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 北京百普赛斯生物科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司 2025 年 1-9 月因股份支付影响当期损益的金额为 8,321,702.80 元，扣除股份支付影响后归属于母公司上市股东的 净利润为 140,748,079.80 元。 公司报告期末至季度报告披露日股本是否因发行新股、增发、配股、股权激励行权、回购等原因发生变化且影响所有者 权益金额 是 □否 | ...

Investment Rating - The report maintains an "Overweight" rating for several pharmaceutical companies including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Jiangsu Nhwa Pharmaceutical, with related targets such as CSPC Innovation Pharmaceutical [6][28]. Core Insights - The innovative drug sector is experiencing high prosperity, and the report continues to recommend innovative drugs and their industry chain. It highlights the recent global strategic collaboration between Innovent Biologics and Takeda, which is expected to catalyze the innovative drug market [6][29]. - The report notes that the A-Shares pharmaceutical sector underperformed the market in the fourth week of October 2025, with the SW Pharmaceutical and Biological index rising only 0.6% compared to a 2.9% increase in the SHCOMP [8][30]. - In the same period, the Hong Kong pharmaceutical sector also underperformed, while the U.S. pharmaceutical sector performed in line with the market [31][19]. Summary by Sections Continuous Recommendation of Innovative Drugs and Industry Chain - The report emphasizes the ongoing recommendation of innovative drugs and the industry chain, maintaining "Overweight" ratings for various companies including Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, and Nhwa Pharmaceutical. It also recommends Biopharma/Biotech companies with innovative pipelines and increasing performance, maintaining "Overweight" ratings for Innovent Biologics, Xiamen Amoytop Biotech, and others [6][28]. Performance of A-Shares Pharmaceutical Sector - In the fourth week of October 2025, the A-Shares pharmaceutical sector's performance was weaker than the overall market, with a 0.6% increase compared to the SHCOMP's 2.9% rise. The medical service, pharmaceutical commerce, and medical equipment sub-sectors showed relatively better performance [8][30]. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector underperformed the market with a decline of 0.8%, while the U.S. pharmaceutical sector matched the market performance with a 1.9% increase. Notable stock movements included significant gains for companies like WuXi AppTec and declines for Alphamab Oncology in Hong Kong [31][19].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]